TY - JOUR
T1 - Current Microbiology of surgical site infections associated with breast cancer surgery
AU - Rolston, Kenneth
AU - Mihu, Coralia
AU - Tarrand, Jeffrey
N1 - Copyright:
Copyright 2010 Elsevier B.V., All rights reserved.
PY - 2010/5
Y1 - 2010/5
N2 - Surgical site infections (SSI) are the most common complications of breast cancer surgery. The authors identified 35 cases of SSI in the M.D. Anderson Cancer Center (Houston, TX) over a 7-month study period. Monomicrobial infections predominated (69%) with Staphylococcus aureus being isolated most often. A wide variety of gram-positive and gram-negative organisms were isolated from the 31% of polymicrobial infections, suggesting the need for broad-spectrum coverage at least until culture results become available. Although all S aureus isolates were susceptible to vancomycin (minimal inhibitory concentration [MIC] ≤ 2.0 μg/mL), 63% of methicillin- susceptible isolates and 82% of methicillin-resistant isolates had MIC values of ≥ 1.0 μg/mL for this agent, indicating the need for alternative therapeutic agents. The organisms were susceptible to trimethoprim/ sulfamethoxazole, rifampin, linezolid, daptomycin, and tigecycline.
AB - Surgical site infections (SSI) are the most common complications of breast cancer surgery. The authors identified 35 cases of SSI in the M.D. Anderson Cancer Center (Houston, TX) over a 7-month study period. Monomicrobial infections predominated (69%) with Staphylococcus aureus being isolated most often. A wide variety of gram-positive and gram-negative organisms were isolated from the 31% of polymicrobial infections, suggesting the need for broad-spectrum coverage at least until culture results become available. Although all S aureus isolates were susceptible to vancomycin (minimal inhibitory concentration [MIC] ≤ 2.0 μg/mL), 63% of methicillin- susceptible isolates and 82% of methicillin-resistant isolates had MIC values of ≥ 1.0 μg/mL for this agent, indicating the need for alternative therapeutic agents. The organisms were susceptible to trimethoprim/ sulfamethoxazole, rifampin, linezolid, daptomycin, and tigecycline.
UR - http://www.scopus.com/inward/record.url?scp=77953096991&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77953096991&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:77953096991
SN - 1044-7946
VL - 22
SP - 132
EP - 135
JO - Wounds
JF - Wounds
IS - 5
ER -